Form 6-K — CureVac N.V.: data from the Phase 1 clinical trial of CV8102 (November 10, 2021)
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of November, 2021, Commission File Number 001-39446. It states that on November 10, 2021 the company issued a press release announcing data from the completed dose-escalation part of a clinical trial of CV8102, its lead oncology candidate. The information is incorporated by reference into a Form F-3 registration statement, File No. 333-259613, and the press release is listed as Exhibit 99.1.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 6-K — CureVac N.V.: data from the Phase 1 clinical trial of CV8102 (November 10, 2021).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2021-11-10-0001104659-21-136607-88050250af/
, SHA-256 c3aa9047ce9b656eed96b9b14e88e078681b769086afc0b3e1e0998a6bed62df.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number: 001-39446 CureVac N.V. ( Exact Name of Registrant as Specified in Its Charter ) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F | x | Form 40-F | ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes | ¨ | No | x Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes | ¨ | No | x On November 10, 2021, CureVac N.V. (the “Company”) issued a press release announcing data from the completed dose-escalation part of the Phase 1 clinical trial of CV8102, the Company’s lead oncology candidate. The information included in this Form 6-K (including Exhibit 99.1, but excluding the statements of CureVac N.V.’s Chief Development Officer contained in Exhibits 99.1 thereto) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: November 10, 2021 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | CureVac N.V. Press Release dated November 10, 2021.
File and source
- File
- SEC_CVAC_6-K_filed2021-11-10_0001104659-21-136607.htm
- Size
- 12,480 bytes
- SHA-256
- c3aa9047ce9b656eed96b9b14e88e078681b769086afc0b3e1e0998a6bed62df
- Original
- www.sec.gov